InnovationRx is a curated collection of healthcare news delivered directly to your inbox. Don’t miss out, subscribe here.
Meet Dr. Carolyn Bertozzi – Stanford Professor and Nobel Prize winner.
Justin Sullivan/Getty Images
Dr. Carolyn Bertozzi achieved a groundbreaking feat by winning the Nobel Prize in Chemistry in 2022 for her contribution to the field of bioorthogonal chemistry, also known as “click” chemistry. These innovative reactions that occur within cells have the potential to enhance the precision and effectiveness of cancer drug targeting. At the age of 55, Dr. Bertozzi, who serves as a research scientist and professor at Stanford University, is a remarkable example of pioneering research in healthcare. Additionally, she has co-founded 8 successful biotech startups, further showcasing her entrepreneurial spirit and dedication to advancing healthcare solutions. Dr. Bertozzi’s achievements have earned her a well-deserved spot on the prestigious Forbes 50 Over 50 list, which highlights exceptional innovators in various industries.
This year’s Forbes 50 Over 50 list also features remarkable individuals leading prominent companies in the healthcare sector. One such figure is Gail Boudreaux, the 63-year-old CEO of Elevance Health (formerly known as Anthem), one of the largest health insurance companies in the United States. Another notable honoree is Sharon Mates, a 70-year-old trailblazer who co-founded and serves as the CEO of Intra-Cellular Therapies, a biopharmaceutical company valued at $5.8 billion. Through relentless innovation, Intra-Cellular Therapies has developed groundbreaking therapies for schizophrenia and bipolar depression. The list also recognizes startup leaders like Gina Bartasi, the visionary founder of Kindbody, a fertility startup that has attracted $315 million in investments from prominent firms like GV and JP Morgan Chase’s Morgan Health. For a comprehensive look at all the extraordinary individuals featured on the Forbes 50 Over 50 list, click here.
Revolutionizing Cancer Treatment with Genetically Engineered Viruses
Meet Arthur Kuan, the CEO of CG Oncology, spearheading a groundbreaking fight against bladder cancer.
Jamel Toppin/The Forbes Collection;
CG Oncology, led by Arthur Kuan, a notable recipient of the Forbes 30 Under 30 accolade, is committed to revolutionizing the treatment of a stagnant form of cancer that has seen little progress over the decades. Recently, CG Oncology announced a successful $105 million crossover funding round aimed at advancing its groundbreaking treatment to phase 3 trials and ultimately, the market. This significant investment will propel the development of a genetically engineered virus that holds immense potential in combating bladder cancer.
To learn more about this groundbreaking treatment, click here.
Latest Pipeline & Deal Updates
Long Covid: The National Institutes of Health have initiated phase 2 clinical trials to evaluate four potential treatments for long Covid.
Artificial Intelligence: BioNTech has completed its strategic $550 million acquisition of InstaDeep, bolstering its efforts to utilize AI in the discovery of novel therapies and vaccines.
Telehealth: Amazon Clinic, launched in November 2022, has expanded its services to all 50 states, forging partnerships with reputable vendors like Wheel, SteadyMD, Curai Health, and Hello Alpha.
New Fund: Reed Jobs, son of the late Apple co-founder Steve Jobs, has successfully raised $200 million for his venture capital firm, Yosemite. Yosemite is focused on funding cutting-edge cancer treatments to bring hope and progress to patients worldwide.
Cancer: The FDA has granted approval for GSK’s Jemperli, in combination with chemotherapy, for frontline treatment in specific patients with advanced or recurrent endometrial cancer. This milestone signifies a major advancement in the fight against this challenging form of cancer.
Empowering Doctors with Real-Time Scientific Knowledge
Introducing Daniel Nadler, founder of OpenEvidence, a revolutionary health AI startup.
© Shawn G. Henry • 978.590.48
Language models have traditionally faced limitations due to their fixed training data. OpenAI’s chatbot ChatGPT, for example, has not been updated since September 2021. To make chatbots more effective in medical settings, access to the latest scientific research is crucial. Daniel Nadler, the visionary founder of OpenEvidence, has dedicated his efforts to tackling this knowledge cutoff problem. With $32 million in capital and a team of highly skilled individuals, including several PhD holders and candidates, Nadler has made significant progress in addressing this issue. OpenEvidence’s innovative approach has attracted $27 million in Series B funding from external investors, valuing the startup at an impressive $425 million as of July 2022.
Discover more about OpenEvidence and its groundbreaking mission here.
Follow Google News
Denial of responsibility! TechCodex is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
Jessica Irvine is a tech enthusiast specializing in gadgets. From smart home devices to cutting-edge electronics, Jessica explores the world of consumer tech, offering readers comprehensive reviews, hands-on experiences, and expert insights into the coolest and most innovative gadgets on the market.
